VYNE Therapeutics Inc.
For the period ended Dec 31, 2025. Filed Feb 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 27, 2026
YARW$15.48-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
CONSOLIDATED STATEMENTS OF CASH FLOWS
| Year ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash Flows From Operating Activities: | ||
| Net loss | $(26,483) | $(39,834) |
| Adjustments required to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 23 | 4 |
| Share-based compensation | 2,308 | 3,303 |
| Amortization of premium or discount on marketable securities | (778) | (2,443) |
| Unrealized loss on cash equivalents | — | (1) |
| Changes in operating assets and liabilities: | ||
| Trade receivables, prepaid expenses and other assets and operating lease right of use assets | 4,214 | (899) |
| Trade payables, accrued expenses, employee related obligations and other long-term liabilities | (12,309) | 6,012 |
| Operating lease liabilities | (99) | (114) |
| Net cash used in operating activities | (33,124) | (33,972) |
| Cash Flows From Investing Activities: | ||
| Purchase of property and equipment | — | (117) |
| Proceeds from the sale and maturity of marketable securities | 68,300 | 84,000 |
| Purchases of marketable securities | (30,932) | (60,518) |
| Net cash provided by investing activities | 37,368 | 23,365 |
| Cash Flows From Financing Activities: | ||
| Withholdings from exercise of options and issuance of shares for stock-based compensation arrangements, net | (143) | (141) |
| Net cash used in financing activities | (143) | (141) |
| Increase (decrease) in cash and cash equivalents | 4,101 | (10,748) |
| Cash and cash equivalents at beginning of the year | 19,926 | 30,674 |
| Cash and cash equivalents at end of the year | $24,027 | $19,926 |
| Supplementary information on investing and financing activities not involving cash flows: | ||
|---|---|---|
| Issuance of vested shares under employee share purchase plan | $16 | $30 |
F - 5
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.